Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Accord is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: helps control acute and delayed episodes in cancer patients. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms during radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea after surgical procedures. - Pregnancy‑related nausea (hyperemesis gravidarum): used when other treatments are ineffective, under specialist specialist specialist specialist specialist specialist.

Common Side Effects: - Headache : mild to moderate headache in many patients. - Constipation : reduced bowel movements or hard stools that may appear after dose administration. - Diarrhoea : loose stools occasion ally during treatment . - Fatigue : feelings of tired or low energy . - Dizziness : light‑headed sensation .

Serious or Rare Side Effects: - QT‑interval prolongation : cardiac rhythm changes that may lead to arrhythmia . - Severe allergic reactions : rash , hives , swelling of the face or throat . - Serotonin syndrome : confusion , agitation , muscle rigidity . - Hepatic enzyme elevation : increased liver function tests . - Vision changes : blurred or abnormal visual perception.

Ondansetron should be used with caution in patients with known cardiac conduction abnormalities.

- Cardiac monitoring: patients with a history of QT prolongation should have ECG monitoring. - Electrolyte balance: correct hypokalemia, hypomagnesemia, or hypocalcaemia before the c . - Concomitant serotonergic drugs: avoid the  . - Pregnancy  :  . - Breast‑  . - Store  :  .

The  .

Major  g  g .

   t """""""""""""""""""""""""""""""""""""""""""""""""""""""" placeholders  .

  """  """"""""""""""""""...